• Product NameTauroursodeoxycholic Acid
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityTauroursodeoxycholic acid is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans. Tauroursodeoxycholic acid, on the other hand, is produced abundantly in bears and has been used for centuries as a natural remedy in some Asian countries. Tauroursodeoxycholic acid is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis. The only completed clinical trial thus far is a phase III clinical trial comparing tauroursodeoxycholic acid and ursofalk in PBC adult patients, but as of June 2013 no results of this trial have been published.
• Target NameP450
• CAS No. 14605-22-2
• Calculated MW 499.7
• Formulation C26H45NO6S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Metabolism system
  SMILES:C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
  Pathways:Metabolism
  Receptor:CYP3A
  Boling pt:
  Melting pt:173-175C
  Solubility:DMSO: 10 mM
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Paolini M, et al. Hepatology. 1999 Sep;30(3):730-9.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting